Cargando…

Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions

Infections of the Coronavirus SARS-CoV-2 continue to spread around the globe, causing Coronavirus Disease (COVID)-19. Infected people are at risk of developing acute interstitial pneumonia, which can result in lethal complications, particularly in patients with pre-existing co-morbidities. Novel pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Renn, Marcel, Bartok, Eva, Zillinger, Thomas, Hartmann, Gunther, Behrendt, Rayk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219947/
https://www.ncbi.nlm.nih.gov/pubmed/34171328
http://dx.doi.org/10.1016/j.pharmthera.2021.107931
_version_ 1783711050447716352
author Renn, Marcel
Bartok, Eva
Zillinger, Thomas
Hartmann, Gunther
Behrendt, Rayk
author_facet Renn, Marcel
Bartok, Eva
Zillinger, Thomas
Hartmann, Gunther
Behrendt, Rayk
author_sort Renn, Marcel
collection PubMed
description Infections of the Coronavirus SARS-CoV-2 continue to spread around the globe, causing Coronavirus Disease (COVID)-19. Infected people are at risk of developing acute interstitial pneumonia, which can result in lethal complications, particularly in patients with pre-existing co-morbidities. Novel prophylactic and therapeutic interventions are urgently needed to limit the infection-associated health risk for the population and to contain the pandemic. Animal models are indispensable to assessing the efficacy and safety of potential new antivirals, vaccines, and other innovative therapies, such as nucleic acid agonists of innate immune sensing receptors. In this review, we provide an overview of the commonly used animal models to study SARS-CoV-2 and COVID-19, including a summary of their susceptibility to infection, the spectrum of symptoms elicited, and the potential for drug development in each model. We hope that this review will help researchers to decide on the right model organism to quickly address their specific scientific questions.
format Online
Article
Text
id pubmed-8219947
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-82199472021-06-23 Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions Renn, Marcel Bartok, Eva Zillinger, Thomas Hartmann, Gunther Behrendt, Rayk Pharmacol Ther Article Infections of the Coronavirus SARS-CoV-2 continue to spread around the globe, causing Coronavirus Disease (COVID)-19. Infected people are at risk of developing acute interstitial pneumonia, which can result in lethal complications, particularly in patients with pre-existing co-morbidities. Novel prophylactic and therapeutic interventions are urgently needed to limit the infection-associated health risk for the population and to contain the pandemic. Animal models are indispensable to assessing the efficacy and safety of potential new antivirals, vaccines, and other innovative therapies, such as nucleic acid agonists of innate immune sensing receptors. In this review, we provide an overview of the commonly used animal models to study SARS-CoV-2 and COVID-19, including a summary of their susceptibility to infection, the spectrum of symptoms elicited, and the potential for drug development in each model. We hope that this review will help researchers to decide on the right model organism to quickly address their specific scientific questions. Elsevier Inc. 2021-12 2021-06-23 /pmc/articles/PMC8219947/ /pubmed/34171328 http://dx.doi.org/10.1016/j.pharmthera.2021.107931 Text en © 2021 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Renn, Marcel
Bartok, Eva
Zillinger, Thomas
Hartmann, Gunther
Behrendt, Rayk
Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
title Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
title_full Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
title_fullStr Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
title_full_unstemmed Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
title_short Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions
title_sort animal models of sars-cov-2 and covid-19 for the development of prophylactic and therapeutic interventions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219947/
https://www.ncbi.nlm.nih.gov/pubmed/34171328
http://dx.doi.org/10.1016/j.pharmthera.2021.107931
work_keys_str_mv AT rennmarcel animalmodelsofsarscov2andcovid19forthedevelopmentofprophylacticandtherapeuticinterventions
AT bartokeva animalmodelsofsarscov2andcovid19forthedevelopmentofprophylacticandtherapeuticinterventions
AT zillingerthomas animalmodelsofsarscov2andcovid19forthedevelopmentofprophylacticandtherapeuticinterventions
AT hartmanngunther animalmodelsofsarscov2andcovid19forthedevelopmentofprophylacticandtherapeuticinterventions
AT behrendtrayk animalmodelsofsarscov2andcovid19forthedevelopmentofprophylacticandtherapeuticinterventions